Welcome to the team, Jeff!
Jeff comes to Nuvera with several years of experience in the life sciences industry within regulatory compliance, regulatory M&A, quality assurance, operations quality, and R&D. His experience spans a diverse range of companies from dynamic startups to global industry leaders, across various stages of the product lifecycle. Most recently, Jeff worked at KPMG, where he supported global life sciences companies in addressing their most pressing quality, regulatory, and process optimization efforts across the value chain. Jeff holds an MS in Biotechnology from Johns Hopkins University and BS in Biological Sciences from University of Maryland.
Outside of his professional life, Jeff enjoys traveling, cooking, exercising, and rooting for Philly sports teams.
Motivation for Joining Nuvera
“I was eager to continue my journey in life sciences consulting, and after engaging with members of the Nuvera team, it became evident that they invest significantly in the success of their employees and clients. Nuvera strategically implements impactful and practical solutions with a patient-centric focus. Their unwavering commitment to elevating healthcare standards and positively impacting the lives of patients spoke volumes about their dedication to excellence.”
Latest Insights
Jump to a slide with the slide dots.
Ashwini Chidirala
Overcoming the Challenges in Bringing Cell & Gene Therapies to Market
Overcome CGT capacity challenges with strategies for forecasting, staffing, and treatment center partnerships.
Read more
Ashwini Chidirala
Overcoming the Challenges in Bringing Cell & Gene Therapies to Market – Part 2
How CGT manufacturers can reduce treatment center burden through better workflows, training, logistics, and system integration.
Read more
Ashwini Chidirala
Overcoming the Challenges in Bringing Cell & Gene Therapies to Market – Part 3
How CGT manufacturers can reduce financial risk and reimbursement burden for treatment centers adopting commercial therapies.
Read more
Natalie Gier
Free Drug and Access Equation: What Regeneron’s Otarmeni Decision Reveals About Specialty Product Access
Free drug removes price barriers, but Otarmeni shows why specialty therapy access still depends on PSPs, payers, and logistics.
Read more
Ashwini Chidirala
Overcoming the Challenges in Bringing Cell & Gene Therapies to Market – Part 4
As cell and gene therapies (CGTs) continue to enter the market, treatment centers have become the primary gatekeepers...
Read more